Last 12 months
Inside the activity.
5 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 3 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Mar 17, 2023 20:51 UTC |
Dolan ChristineSee Remarks
|
GrantClass A Common Stock | 55,775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000027 · wf-form4_167908630038670.xml · nonDerivative · entry 1 Dolan Christine · CIK 0001684273 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,604 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC |
Herde KevinChief Financial Officer
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 143,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000028 · wf-form4_167908631546730.xml · derivative · entry 2 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC |
Herde KevinChief Financial Officer
|
GrantClass A Common Stock | 72,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000028 · wf-form4_167908631546730.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,190 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:51 UTC |
HULL CARLDirector · Chief Executive Officer
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 270,109 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000026 · wf-form4_167908626696366.xml · derivative · entry 3 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,109 Underlying: Class A Common Stock · 270,109 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:51 UTC |
HULL CARLDirector · Chief Executive Officer
|
GrantClass A Common Stock | 147,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000026 · wf-form4_167908626696366.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,519 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC |
Leddy Peter MichaelSee Remarks
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 143,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000029 · wf-form4_167908633193535.xml · derivative · entry 2 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC |
Leddy Peter MichaelSee Remarks
|
GrantClass A Common Stock | 72,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000029 · wf-form4_167908633193535.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,005 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:52 UTC |
ORESHACK KURTGeneral Counsel
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 76,500 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000030 · wf-form4_167908635682539.xml · derivative · entry 2 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,500 Underlying: Class A Common Stock · 76,500 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:52 UTC |
ORESHACK KURTGeneral Counsel
|
GrantClass A Common Stock | 38,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000030 · wf-form4_167908635682539.xml · nonDerivative · entry 1 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,356 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:34 UTC |
Dolan ChristineSee Remarks
|
Tax withholdingClass A Common Stock | 1,956 | $15.23 | $29,789.88 |
DisclosureSEC source: 0001823239-23-000010 · wf-form4_167666965846138.xml · nonDerivative · entry 1 Dolan Christine · CIK 0001684273 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,829 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:32 UTC |
Herde KevinChief Financial Officer
|
Tax withholdingClass A Common Stock | 2,611 | $15.23 | $39,765.53 |
DisclosureSEC source: 0001823239-23-000007 · wf-form4_167666953300244.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,683 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:33 UTC |
HULL CARLDirector · Chief Executive Officer
|
Tax withholdingClass A Common Stock | 9,719 | $15.23 | $148,020.37 |
DisclosureSEC source: 0001823239-23-000008 · wf-form4_167666958156029.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,881 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:34 UTC |
NEEL BRIANSee Remarks
|
Tax withholdingClass A Common Stock | 2,312 | $15.23 | $35,211.76 |
DisclosureSEC source: 0001823239-23-000009 · wf-form4_167666962110921.xml · nonDerivative · entry 1 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,473 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:32 UTC |
ORESHACK KURTGeneral Counsel
|
Tax withholdingClass A Common Stock | 2,312 | $15.23 | $35,211.76 |
DisclosureSEC source: 0001823239-23-000006 · wf-form4_167666947917126.xml · nonDerivative · entry 1 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 22, 2023 Filed Jan 24, 2023 16:15 UTC |
GTCR INVESTMENT XI LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS, LLCDirector · 10% owner
GTCR FUND XI/B LPDirector · 10% owner
GTCR CO-INVEST XI LPDirector · 10% owner
GTCR PARTNERS XI/B LPDirector · 10% owner
|
Disposition to issuerCommon Units · Derivative | 4,575,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002476 · doc4.xml · derivative · entry 2 GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 119,094,026 Underlying: Class A Common Stock · 4,575,170 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer, Maravai Topco Holdings, LLC ("Topco LLC") and MLSH 1 (the "Exchange Agreement"), units of Topco LLC (the "Common Units") (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"), or for cash from a substantially concurrent public offering or private sale (based on the price of the Issuer's Class A common stock in such public offering or private sale). Common Units do not expire. F5 · shares: Reflects Common Units which were forfeited by MLSH 1 for no consideration. F4 · derivative.exercise_date: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer, Maravai Topco Holdings, LLC ("Topco LLC") and MLSH 1 (the "Exchange Agreement"), units of Topco LLC (the "Common Units") (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"), or for cash from a substantially concurrent public offering or private sale (based on the price of the Issuer's Class A common stock in such public offering or private sale). Common Units do not expire. F4 · derivative.expiration_date: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer, Maravai Topco Holdings, LLC ("Topco LLC") and MLSH 1 (the "Exchange Agreement"), units of Topco LLC (the "Common Units") (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"), or for cash from a substantially concurrent public offering or private sale (based on the price of the Issuer's Class A common stock in such public offering or private sale). Common Units do not expire. F6 · ownership.nature: Reflects Common Units owned directly by MLSH 1. Each Common Unit is exchangeable for one share of Class A Common Stock pursuant to the Exchange Agreement. Read SEC document |
| January 22, 2023 Filed Jan 24, 2023 16:15 UTC |
GTCR INVESTMENT XI LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS, LLCDirector · 10% owner
GTCR FUND XI/B LPDirector · 10% owner
GTCR CO-INVEST XI LPDirector · 10% owner
GTCR PARTNERS XI/B LPDirector · 10% owner
|
Disposition to issuerClass B Common Stock | 4,575,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002476 · doc4.xml · nonDerivative · entry 1 GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 119,094,026 F1 · shares: Reflects shares of the Class B common stock, par value $0.01 per share (the "Class B Common Stock"), of Maravai LifeSciences Holdings, Inc.'s (the "Issuer") forfeited by Maravai Life Sciences Holdings, LLC ("MLSH 1") for no consideration. F2 · ownership.nature: Reflects shares of the Class B Common Stock held directly by MLSH 1. MLSH 1 is managed by a board of managers controlled by GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI"). GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of GTCR Co-Invest XI and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, Benjamin J. Daverman, David A. Donmini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class B Common Stock held directly by MLSH 1. F3 · ownership.nature: (Continued From Footnote 2) Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the Class B Common Stock held directly by MLSH 1, and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the Class B Common Stock held directly by MLSH 1 except to the extent of the pecuniary interest therein. Read SEC document |
| October 31, 2022 Filed Nov 9, 2022 17:35 UTC |
Herde KevinChief Financial Officer
|
GrantClass A Common Stock | 478 | $14.11 | $6,744.58 |
DisclosureSEC source: 0001823239-22-000063 · wf-form4_166803332873857.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,294 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 478 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| October 31, 2022 Filed Nov 9, 2022 22:39 UTC |
NEEL BRIANSee Remarks
|
GrantClass A Common Stock | 329 | $14.11 | $4,642.19 |
DisclosureSEC source: 0001823239-22-000064 · wf-form4_166803353298786.xml · nonDerivative · entry 1 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,785 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 329 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| October 31, 2022 Filed Nov 9, 2022 22:35 UTC |
ORESHACK KURTGeneral Counsel
|
GrantClass A Common Stock | 351 | $14.11 | $4,952.61 |
DisclosureSEC source: 0001823239-22-000062 · wf-form4_166803330319291.xml · nonDerivative · entry 1 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,282 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 351 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC |
MARTIN WILLIAM E. IIISee remarks
|
GrantPerformance Stock Units · Derivative | 240,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · derivative · entry 4 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,038 Underlying: Class A Common Stock · 240,038 shares Expires 2025-10-17 F4 · derivative.exercise_price: Represents performance stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on October 17, 2025, if and to the extent the 60-trading day volume-weighted average stock price of the Class A Common Stock of the Issuer equals or exceeds certain thresholds, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to October 17, 2025, the PSUs will convert to time-based RSUs that will fully vest on October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. F4 · derivative.exercise_date: Represents performance stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on October 17, 2025, if and to the extent the 60-trading day volume-weighted average stock price of the Class A Common Stock of the Issuer equals or exceeds certain thresholds, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to October 17, 2025, the PSUs will convert to time-based RSUs that will fully vest on October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC |
MARTIN WILLIAM E. IIISee remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 403,946 | $0.00 Strike: $19.42 | $0.00 |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · derivative · entry 3 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,946 Underlying: Class A Common Stock · 403,946 shares Expires 2032-10-17 F3 · derivative.exercise_date: Represents options awarded under the Omnibus Incentive Plan. These options will vest 25% on October 17, 2023 and in near-equal 1/36th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC |
MARTIN WILLIAM E. IIISee remarks
|
GrantClass A Common Stock | 228,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · nonDerivative · entry 2 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,055 F2 · price: Represents RSUs awarded under the Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of October 17, 2023, October 17, 2024, and October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC |
MARTIN WILLIAM E. IIISee remarks
|
GrantClass A Common Stock | 120,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,019 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest 50% on each of October 17, 2023 and October 17, 2024, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:08 UTC |
Leddy Peter MichaelSee Remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 122,893 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001823239-22-000040 · wf-form4_165826131381082.xml · derivative · entry 2 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,893 Underlying: Class A Common Stock · 122,893 shares Expires 2032-07-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 25% on July 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:08 UTC |
Leddy Peter MichaelSee Remarks
|
GrantClass A Common Stock | 63,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-22-000040 · wf-form4_165826131381082.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,498 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of July 15, 2023, July 15, 2024, and July 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 22:42 UTC |
Dolan ChristineSee Remarks
|
GrantClass A Common Stock | 666 | $22.95 | $15,284.70 |
DisclosureSEC source: 0001823239-22-000027 · wf-form4_165636975122915.xml · nonDerivative · entry 1 Dolan Christine · CIK 0001684273 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,785 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 666 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 19:55 UTC Amendment |
Herde KevinChief Financial Officer
|
GrantClass A Common Stock | 427 | $22.95 | $9,799.65 |
DisclosureSEC source: 0001823239-22-000032 · wf-form4a_165637410200444.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,816 F1 · kind: Amended to note that this is a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 427 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 18:42 UTC |
Herde KevinChief Financial Officer
|
GrantClass A Common Stock | 427 | $22.95 | $9,799.65 |
DisclosureSEC source: 0001823239-22-000026 · wf-form4_165636973465957.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,816 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 427 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 23:55 UTC Amendment |
ORESHACK KURTGeneral Counsel
|
GrantClass A Common Stock | 394 | $22.95 | $9,042.30 |
DisclosureSEC source: 0001823239-22-000034 · wf-form4a_165637414186269.xml · nonDerivative · entry 1 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,931 F1 · kind: Amended to note that this a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 394 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 23:55 UTC Amendment |
NEEL BRIANSee Remarks
|
GrantClass A Common Stock | 572 | $22.95 | $13,127.40 |
DisclosureSEC source: 0001823239-22-000033 · wf-form4a_165637412206107.xml · nonDerivative · entry 1 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,456 F1 · kind: Amended to note that this is a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 572 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 22:43 UTC |
ORESHACK KURTGeneral Counsel
|
GrantClass A Common Stock | 394 | $22.95 | $9,042.30 |
DisclosureSEC source: 0001823239-22-000028 · wf-form4_165636976847363.xml · nonDerivative · entry 1 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,931 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 394 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 22:42 UTC |
NEEL BRIANSee Remarks
|
GrantClass A Common Stock | 572 | $22.95 | $13,127.40 |
DisclosureSEC source: 0001823239-22-000025 · wf-form4_165636971639611.xml · nonDerivative · entry 1 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,456 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 572 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:15 UTC |
PRAHALAD MURALIDirector
|
GiftClass A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003853 · doc4.xml · nonDerivative · entry 3 PRAHALAD MURALI · CIK 0001829991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,823 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:15 UTC |
PRAHALAD MURALIDirector
|
GiftClass A Common Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003853 · doc4.xml · nonDerivative · entry 2 PRAHALAD MURALI · CIK 0001829991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,823 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:15 UTC |
PRAHALAD MURALIDirector
|
GiftClass A Common Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003853 · doc4.xml · nonDerivative · entry 1 PRAHALAD MURALI · CIK 0001829991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,123 Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
Dolan ChristineSee Remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003414 · doc4.xml · derivative · entry 4 Dolan Christine · CIK 0001684273 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Class A Common Stock · 31,500 shares Expires 2032-01-25 F3 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
Dolan ChristineSee Remarks
|
GrantClass A Common Stock | 17,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003414 · doc4.xml · nonDerivative · entry 3 Dolan Christine · CIK 0001684273 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,119 F2 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC |
Herde KevinChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 36,200 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · derivative · entry 4 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,200 Underlying: Class A Common Stock · 36,200 shares Expires 2032-01-25 F3 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC |
Herde KevinChief Financial Officer
|
GrantClass A Common Stock | 19,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · nonDerivative · entry 3 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,389 F2 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC |
HULL CARLDirector · Chief Executive Officer
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 151,200 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003415 · doc4.xml · derivative · entry 3 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,200 Underlying: Class A Common Stock · 151,200 shares Expires 2032-01-25 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC |
HULL CARLDirector · Chief Executive Officer
|
GrantClass A Common Stock | 81,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003415 · doc4.xml · nonDerivative · entry 1 HULL CARL · CIK 0001205465 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,600 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
NEEL BRIANSee Remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003417 · doc4.xml · derivative · entry 4 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Class A Common Stock · 31,500 shares Expires 2032-01-25 F3 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
NEEL BRIANSee Remarks
|
GrantClass A Common Stock | 17,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003417 · doc4.xml · nonDerivative · entry 3 NEEL BRIAN · CIK 0001829754 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,884 F2 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
ORESHACK KURTGeneral Counsel
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003416 · doc4.xml · derivative · entry 4 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Class A Common Stock · 31,500 shares Expires 2032-01-25 F3 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:00 UTC |
ORESHACK KURTGeneral Counsel
|
GrantClass A Common Stock | 17,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003416 · doc4.xml · nonDerivative · entry 3 ORESHACK KURT · CIK 0001832579 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,537 F2 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:05 UTC |
GTCR INVESTMENT XI LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS, LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS 2, LLCDirector · 10% owner
GTCR FUND XI/B LPDirector · 10% owner
GTCR FUND XI/C LPDirector · 10% owner
GTCR CO-INVEST XI LPDirector · 10% owner
GTCR PARTNERS XI/A&C LPDirector · 10% owner
GTCR PARTNERS XI/B LPDirector · 10% owner
|
Disposition to issuerCommon Units · Derivative | 2,570,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-000472 · doc4.xml · derivative · entry 3 GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 123,669,196 Underlying: Class A Common Stock · 2,570,415 shares Expires not disclosed F5 · derivative.exercise_price: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer Maravai Topco Holdings, LLC and MLSH 1 (the "Exchange Agreement"), the Common Units (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"). Common Units do not expire. F5 · derivative.exercise_date: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer Maravai Topco Holdings, LLC and MLSH 1 (the "Exchange Agreement"), the Common Units (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"). Common Units do not expire. F5 · derivative.expiration_date: Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer Maravai Topco Holdings, LLC and MLSH 1 (the "Exchange Agreement"), the Common Units (together with one share of Class B Common Stock for every Common Unit) are exchangeable for one share of the Issuer's Class A common stock, par value $0.01 per share (the "Class A Common Stock"). Common Units do not expire. F6 · ownership.nature: Reflects Common Units owned directly by MLSH 1. Each Common Unit is exchangeable for one share of Class A Common Stock pursuant to the Exchange Agreement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:05 UTC |
GTCR INVESTMENT XI LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS, LLCDirector · 10% owner
MARAVAI LIFE SCIENCES HOLDINGS 2, LLCDirector · 10% owner
GTCR FUND XI/B LPDirector · 10% owner
GTCR FUND XI/C LPDirector · 10% owner
GTCR CO-INVEST XI LPDirector · 10% owner
GTCR PARTNERS XI/A&C LPDirector · 10% owner
GTCR PARTNERS XI/B LPDirector · 10% owner
|
Disposition to issuerClass B Common Stock | 2,570,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-000472 · doc4.xml · nonDerivative · entry 2 GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 123,669,196 F3 · ownership.nature: Reflects shares of the Issuer's Class B Common Stock, par value $0.01 per share (the "Class B Common Stock"), held directly by Maravai Life Sciences Holdings, LLC ("MLSH 1"). MLSH 1 is managed by a board of managers controlled by GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI"). GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI is the general partner of GTCR Co-Invest XI and GTCR Partners XI/B. GTCR Investment XI is managed by the GTCR Board of Managers, and no single person has voting or dispositive authority over the Class B Common Stock. F4 · ownership.nature: (Continued From Footnote 3) Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the Class B Common Stock held of record by MLSH 1, and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the Class B Common Stock held of record by MLSH 1 except to the extent of the pecuniary interest therein. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:15 UTC |
Ashkenazi AnatDirector
|
GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045770 · doc4.xml · nonDerivative · entry 1 Ashkenazi Anat · CIK 0001761679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,123 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:16 UTC |
MIHAS CONSTANTINE SDirector
|
GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045776 · doc4.xml · nonDerivative · entry 1 MIHAS CONSTANTINE S · CIK 0001262930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,271 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:15 UTC |
LUCIER GREGORY TDirector
|
GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045771 · doc4.xml · nonDerivative · entry 1 LUCIER GREGORY T · CIK 0001251299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,123 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.